JP2022505022A - 腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化 - Google Patents

腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化 Download PDF

Info

Publication number
JP2022505022A
JP2022505022A JP2021518633A JP2021518633A JP2022505022A JP 2022505022 A JP2022505022 A JP 2022505022A JP 2021518633 A JP2021518633 A JP 2021518633A JP 2021518633 A JP2021518633 A JP 2021518633A JP 2022505022 A JP2022505022 A JP 2022505022A
Authority
JP
Japan
Prior art keywords
administering
tumor
alpha
substance
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021518633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505022A5 (https=
Inventor
ドマンケヴィッチ、ヴェレッド
ケイサリ、ヨナ
ケルソン、イザーク
Original Assignee
アルファ タウ メディカル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルファ タウ メディカル リミテッド filed Critical アルファ タウ メディカル リミテッド
Publication of JP2022505022A publication Critical patent/JP2022505022A/ja
Publication of JP2022505022A5 publication Critical patent/JP2022505022A5/ja
Priority to JP2024174991A priority Critical patent/JP2025013822A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1007—Arrangements or means for the introduction of sources into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N2005/1019—Sources therefor
    • A61N2005/1024—Seeds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1027—Interstitial radiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021518633A 2018-11-01 2019-10-31 腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化 Pending JP2022505022A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024174991A JP2025013822A (ja) 2018-11-01 2024-10-04 腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862753930P 2018-11-01 2018-11-01
US62/753,930 2018-11-01
PCT/IB2019/059331 WO2020089819A1 (en) 2018-11-01 2019-10-31 Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024174991A Division JP2025013822A (ja) 2018-11-01 2024-10-04 腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化

Publications (2)

Publication Number Publication Date
JP2022505022A true JP2022505022A (ja) 2022-01-14
JP2022505022A5 JP2022505022A5 (https=) 2022-10-19

Family

ID=70464034

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518633A Pending JP2022505022A (ja) 2018-11-01 2019-10-31 腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化
JP2024174991A Pending JP2025013822A (ja) 2018-11-01 2024-10-04 腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024174991A Pending JP2025013822A (ja) 2018-11-01 2024-10-04 腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化

Country Status (13)

Country Link
US (1) US12594291B2 (https=)
EP (2) EP4603098A3 (https=)
JP (2) JP2022505022A (https=)
KR (1) KR20210087949A (https=)
CN (2) CN117338800A (https=)
AU (3) AU2019370892B2 (https=)
CA (1) CA3114299A1 (https=)
ES (1) ES3035872T3 (https=)
HR (1) HRP20250846T1 (https=)
HU (1) HUE072799T2 (https=)
PL (1) PL3873598T3 (https=)
SG (1) SG11202102627PA (https=)
WO (1) WO2020089819A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350431B2 (en) 2011-04-28 2019-07-16 Gt Medical Technologies, Inc. Customizable radioactive carriers and loading system
US9821174B1 (en) 2015-02-06 2017-11-21 Gammatile Llc Radioactive implant planning system and placement guide system
US10888710B1 (en) 2016-11-29 2021-01-12 Gt Medical Technologies, Inc. Transparent loading apparatus
CA3192409A1 (en) * 2020-09-15 2022-03-24 Jan A. Alfheim Preparations of radium-224 and progenies for use in radionuclide therapy in combination with dna repair inhibitors
AU2021400142B2 (en) 2020-12-16 2024-11-21 Alpha Tau Medical Ltd. Diffusing alpha-emitters radiation therapy with enhanced beta treatment
CN113230400A (zh) * 2021-03-11 2021-08-10 上海交通大学 一种基于表观遗传调控的金纳米团簇放疗增敏组装体及其制备和应用
US20220395702A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for glioblastoma
US12076581B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for glioblastoma
US12064643B2 (en) 2021-06-10 2024-08-20 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for breast cancer
US20220395703A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Activity levels for diffusing alpha-emitter radiation therapy
US12070620B2 (en) 2021-06-10 2024-08-27 Alpha Tau Medical Ltd. Activity levels for diffusing alpha-emitter radiation therapy
US20220395701A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for pancreatic cancer
US12076583B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for melanoma
US12042668B2 (en) 2021-06-10 2024-07-23 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for squamous cell carcinoma
US11964168B2 (en) 2021-06-10 2024-04-23 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for prostate cancer
US12070621B2 (en) 2021-06-10 2024-08-27 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for pancreatic cancer
US12076582B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for colorectal cancer
IL309328A (en) * 2021-06-20 2024-02-01 Alpha Tau Medical Ltd Irradiation by intratumoral alpha emitters in combination with vascular inhibitors
IL309327A (en) * 2021-06-20 2024-02-01 Alpha Tau Medical Ltd Irradiation by intratumoral alpha emitters in combination with immune checkpoint regulators
US12053644B2 (en) 2021-12-30 2024-08-06 Gt Medical Technologies, Inc. Radiation shielding apparatus for implantable radioactive seeds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248057B1 (en) 1998-07-28 2001-06-19 Innerdyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
ATE437226T1 (de) 2000-01-31 2009-08-15 Yissum Res Dev Co Selektiv-abtöten von zellen durch aktivierung der doppelsträngiges rns abhängigen proteinkinase - pkr
US20030153083A1 (en) 2000-01-31 2003-08-14 Alexei Shir Selective killing of cells by activation of double-stranded rna dependent protein kniase-pkr
GB0011903D0 (en) 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
RU2284818C2 (ru) 2001-05-10 2006-10-10 Анормед, Инк. Комбинированная химиотерапия
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US7927792B2 (en) 2002-11-18 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Targeted double stranded RNA mediated cell killing
ES2294496T3 (es) 2003-04-30 2008-04-01 Ramot At Tel Aviv University Ltd. Metodo y dispositivo para radioterapia.
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
GB0423565D0 (en) 2004-10-22 2004-11-24 Algeta As Formulation
US7834064B2 (en) 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
CA2615589A1 (en) 2005-07-26 2007-02-01 Ramot At Tel Aviv University Ltd. A radioactive surface source and a method for producing the same
US20080124366A1 (en) 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
US20090088401A1 (en) 2007-09-27 2009-04-02 Andres Salazar In-situ cancer autovaccination with intratumoral stabilized dsRNA viral mimic
EP2247308A4 (en) 2008-01-10 2012-04-18 Nventa Biopharmaceuticals Corp AUXILIARY COMPOSITIONS WITH POLY-IC AND A CATIONIC POLYMER
US20090234628A1 (en) * 2008-03-14 2009-09-17 Siemens Medical Solutions Usa, Inc. Prediction of complete response given treatment data
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
US8821364B2 (en) 2008-09-02 2014-09-02 Battelle Memorial Institute Brachytherapy seed with fast dissolving matrix for optimal delivery of radionuclides to cancer tissue
US9006406B2 (en) 2008-12-22 2015-04-14 Alexander Levitzki EGFR-homing double-stranded RNA vector for systemic cancer treatment
WO2011024172A2 (en) 2009-08-27 2011-03-03 Technion Research & Development Foundation Ltd. Liposomal compositions and uses of same
CA2787260A1 (en) * 2010-01-18 2011-07-21 Zhi-Min Yuan Methods and compositions for nanoparticle-mediated cancer cell-targeted delivery
JP5860874B2 (ja) 2010-06-22 2016-02-16 デエヌア・テラプーティックＤｎａｔｈｅｒａｐｅｕｔｉｃｓ 核酸コンジュゲートのためのエンドソーム溶解剤を用いた最適化ｉｎｖｉｖｏ送達システム
CN104411331B (zh) 2012-01-13 2018-08-21 哈佛学院董事会 在结构聚合装置中tlr激动剂的控制传递
US10421971B2 (en) 2014-01-15 2019-09-24 The University Of Chicago Anti-tumor therapy
EP4245376A3 (en) * 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2017025496A1 (en) * 2015-08-12 2017-02-16 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
CN105031648A (zh) * 2015-08-25 2015-11-11 徐州医学院 新型靶向纳米粒子及其制备方法和用途
EP3319587B1 (en) 2015-11-17 2019-08-21 Bioncotech Therapeutics, S.L Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
WO2017173101A1 (en) * 2016-03-30 2017-10-05 Virginia Commonwealth University Combination therapy for neuroblastoma using mda-7/il-24 with therapeutic agents
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
IL264557B2 (en) 2016-08-02 2024-01-01 Harvard College Biological agents for regulating immune responses
AU2017321609C1 (en) * 2016-08-30 2023-11-09 Dana-Farber Cancer Institute, Inc. Drug delivery compositions and uses thereof
JP7096249B2 (ja) 2016-09-04 2022-07-05 ターグイミューン セラピューティクス アーゲー ｄｓＲＮＡを標的化するためのキメラタンパク質
EP3321362A1 (en) * 2016-11-10 2018-05-16 Centre Leon Berard Tlr3 agonist for use for inducing apoptosis in senescent cancer cells
US11642346B2 (en) * 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
WO2018185135A1 (en) * 2017-04-05 2018-10-11 Boehringer Ingelheim International Gmbh Anticancer combination therapy
CN120643844A (zh) 2017-05-11 2025-09-16 阿尔法陶医疗有限公司 用于近距离放射治疗装置的聚合物涂层
US10849921B2 (en) 2017-05-17 2020-12-01 Bioncotech Therapeutics Sl Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
IL273195B2 (en) 2017-09-27 2024-04-01 Targimmune Therapeutics Ag Castration-resistant prostate cancer
WO2019173456A1 (en) * 2018-03-06 2019-09-12 Board Of Regents, The University Of Texas System Replication stress response biomarkers for immunotherapy response
KR20240172761A (ko) 2018-03-08 2024-12-10 알파 타우 메디컬 리미티드 방사선 요법 시드 및 어플리케이터
EP3762417A1 (en) 2018-03-08 2021-01-13 TargImmune Therapeutics AG A recombinant protein comprising a double stranded rna binding domain
WO2019193464A1 (en) 2018-04-02 2019-10-10 Alpha Tau Medical Ltd. Controlled release of radionuclides
EP3856256A1 (en) * 2018-09-26 2021-08-04 Ascendis Pharma A/S Novel hydrogel conjugates
KR20210146952A (ko) 2019-04-03 2021-12-06 타르그이뮨 테라퓨틱스 아게 암의 치료를 위한 면역요법
JP7372706B2 (ja) 2019-10-10 2023-11-01 アルファ タウ メディカル リミテッド 放射線治療源の湿式調製

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CONFINO, H. ET AL.: "Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation com", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 65, no. 10, JPN6023049959, 2016, pages 1149 - 1158, ISSN: 0005338394 *
CONFINO, H. ET AL.: "Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 64, no. 2, JPN6023049960, 2015, pages 191 - 199, ISSN: 0005338395 *
DOMANKEVICH-BACHAR, V. ET AL.: ""Alpha radiation-based ablation of solid tumors acts as in situ vaccination and activates anti-tumor", CANCER MICROENVIRONMENT, vol. Vol.11, Suppl.1, JPN6023049966, June 2018 (2018-06-01), pages 87 - 1, ISSN: 0005338393 *
QIU, H. ET AL.: "DNA methyltransferase inhibitor 5-aza-CdR enhances the radiosensitivity of gastric cancer cells", CANCER SCIENCE, vol. 100, no. 1, JPN6023049961, 2009, pages 181 - 188, ISSN: 0005211245 *
WU, C. Y. ET AL.: "Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor imm", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 60, no. 8, JPN6023049963, 2011, pages 1085 - 1096, ISSN: 0005211247 *
大島 久美，一戸 辰夫: "免疫調節性薬剤(IMiDs)", 日本臨床, vol. 第72巻，第6号, JPN6023049962, 2014, pages 1130 - 1135, ISSN: 0005211246 *
小檜山 康司，石井 健: "がん免疫療法に資する免疫核酸医薬を基盤としたアジュバントの開発", 癌と化学療法, vol. 第42巻，第9号, JPN6023049965, 2015, pages 1040 - 1045, ISSN: 0005211248 *
藤原 俊義: "テロメラーゼ活性を標的とするアデノウイルス製剤による放射線増感作用", 癌の臨床, vol. 第55巻，第12号, JPN6023049967, 2009, pages 875 - 879, ISSN: 0005211249 *

Also Published As

Publication number Publication date
KR20210087949A (ko) 2021-07-13
AU2023208136A1 (en) 2023-08-17
CN117338800A (zh) 2024-01-05
EP3873598C0 (en) 2025-07-02
CN112912137A (zh) 2021-06-04
EP4603098A2 (en) 2025-08-20
JP2025013822A (ja) 2025-01-28
AU2025230719A1 (en) 2025-10-02
CA3114299A1 (en) 2020-05-07
CN112912137B (zh) 2023-11-21
SG11202102627PA (en) 2021-05-28
HUE072799T2 (hu) 2025-12-28
AU2019370892A1 (en) 2021-04-22
PL3873598T3 (pl) 2025-11-17
EP3873598A1 (en) 2021-09-08
HRP20250846T1 (hr) 2025-09-12
WO2020089819A1 (en) 2020-05-07
US12594291B2 (en) 2026-04-07
US20210379096A1 (en) 2021-12-09
EP3873598A4 (en) 2022-07-20
EP3873598B1 (en) 2025-07-02
AU2023208136B2 (en) 2025-06-12
AU2019370892B2 (en) 2023-04-27
ES3035872T3 (en) 2025-09-10
EP4603098A3 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
JP2022505022A (ja) 腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化
Luo et al. Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy
Domankevich et al. RIG-1-like receptor activation synergizes with intratumoral alpha radiation to induce pancreatic tumor rejection, triple-negative breast metastases clearance, and antitumor immune memory in mice
US12263219B2 (en) Therapeutic composition and method combining multiplex immunotherapy with cancer vaccine for the treatment of cancer
ES2539584T3 (es) Tecnologías de plataforma para enfermedades de origen espontáneo
Serre et al. Brachytherapy: perspectives for combined treatments with immunotherapy
CA3214965A1 (en) Targeting multiple t cell types using spherical nucleic acid vaccine architecture
RU2819734C2 (ru) Излучение внутриопухолевого альфа-излучателя и активация цитоплазматических рецепторов к внутриклеточному патогену
JP2025520663A (ja) 交流電場とｃｒｉｓｐｒ－ｃａｓシステムを用いた症状および疾患の治療システムおよび方法
HK40049032A (en) Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen
HK40101431A (zh) 肿瘤内α粒子-发射体辐射和针对细胞内病原体的细胞质传感器的激活
US20240285820A1 (en) Intratumoral Alpha-Emitter Radiation in Combination with Immune Checkpoint Regulators
HK40049032B (zh) 肿瘤内α粒子-发射体辐射和针对细胞内病原体的细胞质传感器的激活
Kuraku et al. Novel Therapeutic Options for Prevention and Management of Cancer
HK40102661A (zh) 与免疫检查点调节剂组合的肿瘤内α -发射体辐射
Yılmaz et al. Treatment Methods in Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240604

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20241003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241003